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r Robert M. Mentzer (Detroit, Mich). Dr Mieno, I congratulate
ou and your colleagues on your efforts to help us better understand
he impact of aging on VEGF-stimulated angiogenesis. The magni-
ude of your work should not be underestimated. The use of a
reparation that allows one to assess the effect of various stimuli in the
resence and absence of VEGF on the microcirculation of human
trial tissue is quite innovative and represents a significant achieve-
ent in itself.
The first question I have for you relates to your findings in
egard to the intracellular signaling events. As you are aware, there
re numerous signaling molecules that have been associated with
EGF. I am curious to learn more about the rationale you used for
he selection of the molecules you elected to study, since there are
umerous other distant pathway signaling molecules that have
een implicated in VEGF-stimulated angiogenesis. These include
he mitogen-activated protein kinases, the p38 MAPK, phospho-
ipase C, and protein kinase C.
Dr Mieno. In this study, we looked at specific VEGFR2
ignaling pathways, because the VEGFR2 signaling pathway is
ore important for the development of angiogenesis than the
EGFR1 signaling pathways and other signaling pathways such as
rotein kinase C and those you have suggested. We have not
ooked at other signaling pathways.
Dr Mentzer. In regard to the experimental design, it would be
elpful if you would comment on the challenges and limitations of
tudying both aging and VEGF in the context of using CP/CPB.
ince this setting introduces a number of complex variables, is it
ikely that your findings reflect observations that are limited to this
etting? Would you also comment on some of the contributing
actors that might be considered unique to CP/CPB?
Dr Mieno. I think CP/CBP is important to induce ischemic or
xidative stress. Recent publications demonstrated that VEGF
ignaling is altered by ischemia and other kinds of stress. I think
P/CPB is one of the activators of VEGF signaling pathways.
It is easy to get human atrial tissue before and after CPB. And
P/CPB also induces ischemia or reperfusion injury in tissue. That
s why we are looking at difference in VEGF signaling pathway
efore and after CPB.
Dr Mentzer. Finally, I would like to hear your thoughts on
hy the results with VEGF in the surgical setting have been m
The Journal of Thoracicisappointing. Five years ago there was considerable enthusiasm
or VEGF therapy. At this very organization there were reports of
oth preclinical studies and phase I clinical trials that seemed to
ndicate a very promising role for this growth factor. The results
uggested improvement in ventricular function and, at the very
east, relief from disabling angina. As you pointed out in your first
lide, this no longer appears to be the case. On the basis of the
reclinical work presented today, what does the future hold for us
s it relates to VEGF gene therapy? What are your thoughts as to
here we should go from here?
Dr Mieno. As shown in this presentation, mobilization re-
ponse and coronary microvascular relaxation are important fac-
ors for development of angiogenesis. We demonstrated that events
uch as coronary microvascular relaxation and the progenitor mo-
ilization response were impaired by aging as well as after CPB.
his impaired response may be associated with limited develop-
ent of angiogenesis in human clinical trials using the VEGF
rotein. In the clinical setting, if we try to perform cell and protein
herapy, some additional treatment to improve the coronary micro-
ascular relaxation may be required in advance. Previously, we have
emonstrated that L-arginine supplementation, an NO donor, is able to
ormalize the impaired coronary microvascular response in ischemic
eft ventricular tissues of swine models of chronic ischemia.
Dr Sellke. Maybe I can add that there are some intrinsic problems
ith the myocardium in patients requiring angiogenic therapy. zHy-
ercholesterolemia, diabetes, oxidative stress, and other factors affect
he effectiveness of the angiogenic process. Protein growth factors do
ot work, nor does gene therapy work well in these patients. We have
o overcome these inhibitory factors before gene therapy or other
ypes of angiogenic therapy will become effective.
Dr Guo-Wei He (Hong Kong, China). There have been studies
howing that there are two subtypes of VEGF receptors, predom-
nantly on the vascular endothelial cell, KDR receptors (VEGFR2)
nd Flt receptors (VEGFR1). You have not used antagonists for
ither KDR or Flt receptors. Could you please comment on why
ou did not do it or whether you plan to do that.
Second, the diminished response of the microvascular circulation
o VEGF could be due to two reasons: (1) endothelial response
educed or (2) smooth muscle cell response reduced. Which one do
ou think is the factor in the patients with impaired VEGF response?
Dr Mieno. The first question is, as you suggested, that there are
wo major signaling pathways, VEGFR1 and VEGFR2, but we
ave not differentiated the specific signaling pathways in coronary
icrovascular relaxation.
Dr He. Is VEGFR2 related to KDR or related to Flt?
Dr Mieno. We have not used specific antibodies like VEGFR1
r VEGFR2, so I am not sure which pathway is predominantly
nvolved in the coronary microvascular relaxation to VEGF.
Dr He. My second question is, is it due to the diminished
esponse of the endothelial cell or smooth muscle cell?
Dr Mieno. The reduced coronary microvascular relaxation
s due to endothelial dysfunction as well as smooth muscle
ysfunction. I did not show the data for coronary microvascular
elaxation to SNP because of the time limitation, but we have
hose data. The coronary microvascular relaxation to SNP was
mpaired in older patients after CPB. This suggests smooth
uscle cell dysfunction.
and Cardiovascular Surgery ● Volume 132, Number 6 1355
